How has been the historical performance of Onyx Biotec?

Answer:The historical performance of Onyx Biotec shows a consistent growth trajectory in net sales and profitability over the past three fiscal years. Breakdown: Onyx Biotec's net sales increased from 39.48 Cr in Mar'23 to 53.75 Cr in Mar'24, and further to 61.95 Cr in Mar'25, indicating a strong upward trend. Total operating income mirrored this growth, reaching 61.95 Cr in Mar'25. The company's total expenditure also rose, from 35.03 Cr in Mar'23 to 51.61 Cr in Mar'25, primarily driven by an increase in raw material costs and employee expenses. Operating profit (PBDIT) improved significantly from 4.58 Cr in Mar'23 to 11.51 Cr in Mar'25, with a corresponding increase in the operating profit margin from 11.27% to 16.69%. Profit before tax followed suit, rising from 2.55 Cr in Mar'23 to 6.48 Cr in Mar'25, while profit after tax also saw a substantial increase from 1.84 Cr to 4.95 Cr during the same period. The earnings per share (EPS) grew from 1.56 in Mar'23 to 3.72 in Mar'25, reflecting enhanced shareholder value. On the balance sheet, total assets increased from 74.14 Cr in Mar'24 to 91.25 Cr in Mar'25, with total liabilities rising from 74.14 Cr to 91.25 Cr, primarily due to a reduction in long-term borrowings. Cash flow from operating activities remained stable, contributing to a net cash inflow of 7.00 Cr in Mar'25, up from 1.00 Cr in Mar'24. Overall, Onyx Biotec has demonstrated robust growth in sales, profits, and cash flow, positioning itself favorably in the market.